We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
BORTEZOMIB BAXTER (Baxter Healthcare Pty Ltd)
Product name
BORTEZOMIB BAXTER
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
100 (255 working days)
Active ingredients
Bortezomib
Registration type
New generic medicine
Indication
BORTEZOMIB BAXTER, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.
BORTEZOMIB BAXTER, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.
BORTEZOMIB BAXTER is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.
BORTEZOMIB BAXTER in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.